208 related articles for article (PubMed ID: 9138399)
1. Drugs inducing or aggravating parkinsonism: a review.
Marti-Massó JF; Poza JJ; Lopez de Munain A
Therapie; 1996; 51(5):568-77. PubMed ID: 9138399
[TBL] [Abstract][Full Text] [Related]
2. [Drug treatment of frequent disorders in patients with Parkinson's disease].
Martí Massó JF; Poza JJ; López de Munain A
Neurologia; 1996 Mar; 11(3):109-15. PubMed ID: 8695142
[TBL] [Abstract][Full Text] [Related]
3. [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance].
Llau ME; Nguyen L; Senard JM; Rascol O; Montastruc JL
Rev Neurol (Paris); 1994 Nov; 150(11):757-62. PubMed ID: 7597368
[TBL] [Abstract][Full Text] [Related]
4. Case studies in the advancement of Parkinson's disease.
Frei K; Truong DD; Wolters E
CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
[TBL] [Abstract][Full Text] [Related]
5. [Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease].
Errea-Abad JM; Ara-Callizo JR; Aibar-Remón C
Rev Neurol; 1998 Jul; 27(155):35-9. PubMed ID: 9674021
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease.
Barboi AC; Goetz CG
Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
[No Abstract] [Full Text] [Related]
7. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
8. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis of manganese-induced parkinsonism.
Cersosimo MG; Koller WC
Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
[TBL] [Abstract][Full Text] [Related]
10. Drug Insight: new drugs in development for Parkinson's disease.
Colosimo C; Fabbrini G; Berardelli A
Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
[TBL] [Abstract][Full Text] [Related]
11. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
12. Parkinsonism--drug treatment: Part II.
Berg MJ; Ebert B; Willis DK; Host T; Fincham RW; Schottelius DD
Drug Intell Clin Pharm; 1987 Feb; 21(2):167-72. PubMed ID: 3549213
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced parkinsonism after allogeneic bone marrow transplantation.
Pavletic ZS; Bishop MR; Markopoulou K; Wszolek ZK
Bone Marrow Transplant; 1996 Jun; 17(6):1185-7. PubMed ID: 8807135
[TBL] [Abstract][Full Text] [Related]
14. Cinnarizine-induced parkinsonism: ten years later.
Martí-Massó JF; Poza JJ
Mov Disord; 1998 May; 13(3):453-6. PubMed ID: 9613736
[TBL] [Abstract][Full Text] [Related]
15. Diabetes mellitus and drug-induced Parkinsonism: a case-control study.
Ma HI; Kim JH; Chu MK; Oh MS; Yu KH; Kim J; Hahm W; Kim YJ; Lee BC
J Neurol Sci; 2009 Sep; 284(1-2):140-3. PubMed ID: 19467671
[TBL] [Abstract][Full Text] [Related]
16. The history of dopamine and levodopa in the treatment of Parkinson's disease.
Fahn S
Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
[TBL] [Abstract][Full Text] [Related]
17. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease.
Morley JF; Duda JE
J Parkinsons Dis; 2014; 4(2):169-73. PubMed ID: 24284418
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Fahn S
Adv Neurol; 1983; 37():267-76. PubMed ID: 6858776
[TBL] [Abstract][Full Text] [Related]
19. Failure of recognition of drug-induced parkinsonism in the elderly.
Esper CD; Factor SA
Mov Disord; 2008 Feb; 23(3):401-4. PubMed ID: 18067180
[TBL] [Abstract][Full Text] [Related]
20. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
